HEPP News, Vol. 5 No. 5 by HIV & Hepatitis Education Prison Project
University of Rhode Island
DigitalCommons@URI
Infectious Diseases in Corrections Report (IDCR)
2002
HEPP News, Vol. 5 No. 5
HIV & Hepatitis Education Prison Project
Follow this and additional works at: http://digitalcommons.uri.edu/idcr
This Article is brought to you for free and open access by DigitalCommons@URI. It has been accepted for inclusion in Infectious Diseases in
Corrections Report (IDCR) by an authorized administrator of DigitalCommons@URI. For more information, please contact
digitalcommons@etal.uri.edu.
Recommended Citation
HIV & Hepatitis Education Prison Project, "HEPP News, Vol. 5 No. 5" (2002). Infectious Diseases in Corrections Report (IDCR). Paper
35.
http://digitalcommons.uri.edu/idcr/35
Brown Medical School         Providence, RI 02906         401.277.3651         fax: 401.277.3656         www.hivcorrections.org
Safe Steering and the
Global AIDS Crisis
Bill Gates, founder of Microsoft, opened the 9th
Conference on Retroviruses and Opportunistic
Infections (9th CROI) as keynote speaker by
comparing the AIDS epidemic in Africa to the
sinking of the Titanic. This analogy is extremely
apt, for not only is it proving difficult to gauge the
severity of the epidemic by examining the tips of
the icebergs (those known to be infected), but it
also appears that the number of lifeboats on
board (available treatments) is inadequate to
ensure the safety of all the passengers.
Although Bill Gates did not elaborate further, he
clearly implied that passengers in steerage may
not be aware of existing disparities between their
chances of survival compared to passengers
holding a higher class of ticket.  He invoked phil-
anthropy as one potential solution to the global
AIDS crisis, and asked every conference partici-
pant to view those afflicted by HIV/AIDS as their
neighbors in the world village and to engage in
the battle against AIDS on pure humanitarian
grounds. 
This article will review aspects of the 9th CROI
relevant to the management of HIV and hepatitis
in correctional settings. The impact of research
reported at the CROI on the current manage-
ment of HIV infection, as summarized in HHS
guidelines (last updated Feb. 4, 2002), will also
be presented.
Starting Controversy
In only a few short years, recommendations on
initial antiretroviral treatment in the treatment-
naïve individual have completely changed
course. In 1996, the "hit early, hit hard" approach
to HIV management was unveiled by David Ho
and colleagues at the World AIDS conference in
Vancouver. Their recommendation for early,
intense therapy was based on the results of
mathematical models that predicted that HIV
infection could be eradicated from infected cells
in a matter of years if viral replication were com-
pletely suppressed.1 Unfortunately, these early
models of HIV replication were flawed because it
was not known at the time that HIV could persist
for decades in resting T cells, macrophages, and
other "sanctuary" sites.  It is now recognized that
this persistent virus is a source for renewed viral
replication and infection of other cells when
HAART is discontinued.2
Gradually, optimistic sessions on "HIV
Eradication" at the annual CROI meeting have
given way to sessions focusing on optimizing the
durability of therapeutic response and limiting
drug toxicity using strategic treatment interrup-
tion (STI), immunotherapy, and other strategies
which reduce exposure to or even obviate the
need for antiretroviral therapy.3 This year, initial
hopes for interrupted therapy were dashed as
STI was put to "R.I.P." (rest in peace) by Bernard
Hirschel, who summarized data from the Swiss
Spanish Intermittent Therapy Trial (SSITT).4
Reports on the long term side effects associated
with HAART also became more numerous
(Adverse Events will be covered in Update Part
Two in the June/July issue of HEPP News;
Volume 5, Issue 6/7). 
In the "Controversies" session of the CROI con-
ference, Richard Chaisson, M.D., of Johns
Hopkins University raised another note of cau-
tion and proposed that we temper our enthusi-
asm for early treatment by considering the
potential for treatment-related adverse events
along with new data on patient outcomes when
deciding when to initiate treatment.5 This more
cautious approach to the initiation of  HAART is
also reflected in the most recent version of  the
HHS Guidelines for the management of HIV
infection in Adults and Adolescents6 (Table 1):
"While randomized clinical trials provide strong
evidence for treating patients with <200 CD4+ T
cells/mm3, the optimal time to initiate antiretrovi-
ral therapy among asymptomatic patients with
CD4+ T cell counts >200 cells/mm3 is not
known. For individuals with >200 CD4+ T
cells/mm3, the strength of the recommendation
for therapy must balance the readiness of the
patient for treatment, consideration of the prog-
nosis for disease-free survival as determined by
baseline CD4+ T cell count and viral load levels,
and assessment of the risks and potential
benefits associated with initiating antiretroviral
therapy." 6
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An important new concept that was dis-
cussed at the meeting was the "AUC" or
"area under the curve" for HIV viral load.
There appears to be a good correlation, as
expected, between viral load AUC and clin-
ical outcomes. It should come as no sur-
prise that lower viral load AUC (fewer
detectable viral loads or lower viral loads
measured at several time points during
therapy) were directly correlated with
patient adherence and combination thera-
py potency. This relationship between
adherence and outcomes is emphasized in
the HHS guidelines: "patient readiness"is
to be used as a key determinant for initiat-
ing therapy.6
Starting at <200 CD4
Due in part to the ability of HAART to lower
viral loads for prolonged periods of time,
new data from longitudinal cohort studies
appears to demonstrate that delaying
HAART may not be detrimental in the con-
text of the current standard of HIV care in
developed countries (in Europe, the US or
Australia, where the cohort studies were
located). One study by a group in Europe7
showed that virologic suppression can be
achieved even when starting HAART at
CD4+ T cell <200, and that the level of viro-
logic suppression achieved was equivalent
to starting HAART at >350. At first glance,
this appeared to contrast with another
report by Sterling et al., which indicated
that starting HAART at higher CD4+ T cell
appeared to be associated with improved
clinical outcomes.8,9 However, Richard
Chaisson, one of the investigators, pointed
out that even in this study, the beneficial
effects of early treatment were eliminated
when controlling for the viral load AUC.5,8 In
other words, patients who achieved similar-
ly low viral loads did equally well whether
they were started at <200 or <350.8 Dr
Chaisson was emphatic, stating "Patients
started on antiretroviral therapy with CD4+
T cell counts >350 are likely to experience
considerable toxicity as well as emergence
of drug-resistant virus in the absence of a
compelling clinical benefit. Initiation of ther-
apy should be based on CD4+ T cell count
and the patient's ability to comply with com-
plex and potentially toxic regimens."5
Starting at >350 CD4
In contrast,  several clinical studies pre-
sented at the 9th CROI appeared to
demonstrate that earlier HAART initiation
(at CD4+ T cells >350) might be advanta-
geous. David Cooper, from the Sydney
(Australia) AIDS group10 showed that
immune function could be restored in
patients who started HAART later, but the
durability of the restoration might be
decreased. In that study, as in the
EUROSIDA study, baseline CD4+ T cell
count at initiation of therapy determined
which patients would achieve CD4+ T cell
counts above 500 cells/mm3 with HAART.11
Another study by the Hopkins group
(Palella et al.) showed that initiation of
HAART at CD4+ T cell 201-350/mm3 was
associated with reduction in mortality in
comparison with patients for whom HAART
was delayed until they reached a lower
CD4+ T cell count.12 Thus, individual clini-
cians will need to continue to use their dis-
cretion when considering when to start
therapy. Perhaps all of these studies are
best interpreted as indicating that patients
who are highly motivated (and expected to
achieve lower viral load AUC) might
choose to initiate therapy at lower CD4+ T
cell counts (<200) and still achieve excel-
lent virologic response. Delaying therapy
may have other important effects on the
overall epidemic: (1) HIV is more easily
transmitted by persons who are HIV infect-
ed and not on treatment and (2) delayed
treatment may impair the reconstitution of
anti-HIV immune responses - which may
become more important as therapeutic HIV
vaccines advance to Phase III trials. The
bottom line is that the whole patient (med-
ical status, psychosocial context, motiva-
tion, etc.) must be considered.
Despite these revisions to the guidelines,
not all HIV treaters are convinced that
delayed treatment is the optimal strategy.
As Brigitte Autran (Pitié-Salpétrière, Paris,
France) explained in her opening day ple-
nary talk, HIV immunopathogenesis data
seems to indicate that starting HAART ear-
lier may preserve T cell responses that are
specifically directed against HIV, which are
associated with better control of chronic
infection.13 In her plenary talk on immune
restoration, Autran postulates that the early
recovery of anti-opportunistic infection (OI)
CD4+ T cell response is due to the pres-
ence of chronic OI. She provided data
showing that Tetanus, CMV, and Candida
responses return after HAART, but not with
anti HIV-specific help: the CD4+ T cells
specific for HIV that had been erased soon
after primary infection do not reconstitute,
while the preexisting CD8+ T cells
decrease in direct proportion with the viral
oad.13 Such data, as well as information
presented at the 9th CROI on once-a-day
regimens and 2nd generation ART drugs
with fewer side effects, may eventually re-
shift treatment recommendations towards
earlier (>350 CD4+ T cells/mm3) treatment
in the future.
Impact of Clinical Care
In what now appears to be an annual
update on the impact of access to special-
ty care in HIV morbidity and mortality,
Kitahata and colleagues reported that the
risk of HIV disease progression and death
was determined by whether or not patients
received HAART within 12 months of their
initial clinic visit (this study cohort consisted
of 238 patients receiving care at a universi-
ty-affiliated HIV clinic). CD4+ T cell counts
2
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Table 1: Indications for Initiating HAART in HIV-1 Infected Patients
Clinical
Category
Symptomatic
(AIDS, severe
symptoms)
Asymptomatic,
AIDS
Asymptomatic
Asymptomatic
Asymptomatic
CD4+ T Cell
Count
Any value
<200/mm3
>200/mm3 but
<350 mm3
>350/mm3
>350/mm3
Plasma HIV
RNA
Any value
Any value
Any value
>55,000 
(by bDNA or 
RT-PCR)
<55,000 
(by bDNA or 
RT-PCR)
^Clinical benefit has been demonstrated in controlled trials only for patients with CD4+ T cells
<200/mm3. However, most experts would offer therapy at a CD4+ T cell threshold <350/mm3. A
recent evaluation of data from the MACS cohort of 231 individuals with CD4+ T cell counts >200
and <350 cells/mm3 demonstrated that of 40 (17%) individuals with plasma HIV RNA <10,000
copies/ml, none progressed to AIDS by 3 years (Alvaro Munoz, personal communication). Of 28
individuals (29%) with plasma viremia of 10,000-20,000 copies/mL, 4% and 11% progressed to
AIDS at 2 and 3 years respectively. Plasma HIV RNA was calculated as RT-PCR values from
measured bDNA values. For further information, see the full HHS guidelines.
Adapted from HHS guidelines, updated February 4, 2002, p.376
Recommendation
Treat
Treat
Treatment should generally be offered,
though controversy exists.^
Some experts would recommend initiat-
ing therapy, recognizing that the 3-year
risk of developing AIDS in untreated
patients is >30% and some would defer
therapy and monitor CD4+ T cell
counts more frequently.
Many experts would defer therapy and
observe, recognizing that the 3-year
risk of developing AIDS in untreated
patients is 15%.
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Dear Colleagues:
The two themes that run through this issue of HEPP News are the changing standards of HIV
care and women's issues.  
Most of us are wary of changes of any sort because change may result in confusion, suspi-
cion, and extra work.  With regard to HIV care, the standard for initiating antiretroviral therapy
in asymptomatic individuals has changed from relatively early intervention (CD4 count < 500
cells per cc of blood or viral load greater than 20,000 copies per cc of blood) to delayed ther-
apy (CD4 < 350 cells/cc and VL > 55,000). The main article provides a summary of the latest
HIV research that was presented at the 9th Conference on Retroviruses and Opportunistic
Infections (February 24 - 28, 2002, Seattle, Washington) and also highlights the changes in the
HHS treatment guidelines. The results of clinical trials and other research provide us, the clin-
icians, with the evidence upon which to base our medical treatment. Within the prison, adher-
ence to these new guidelines will probably result in fewer patients on antiretroviral therapy.
While this may please administrators who oversee the budget for medical care, it may also
arouse suspicion in inmates who suspect we are skimping on their care.  So clinicians will have
to work extra hard to educate themselves and their patients about the pros and cons of early
versus delayed therapy. Testing in correctional settings also continues to be a high priority,
given the large number of people who do not know they are infected. You can expect to see
more changes in future guidelines as the latest research results are incorporated into evi-
dence-based medicine, the most rational way of treating medical conditions.
Because Mother's Day occurs in May, HEPP News has, according to our tradition, included a
spotlight on women and HIV. Unfortunately, as this spotlight indicates, there is still a relative
dearth of research on women's issues. Nonetheless some encouraging information has been
reported: low-grade cervical lesions in HIV-positive women may have a lower than expected
frequency of progression to neoplasia and mother-to-child transmission of HIV can almost be
eliminated if the mother receives antiretroviral therapy to reduce the VL to undetectable levels. 
After reading this issue, providers should understand the changes in the HHS guidelines, be
familiar with the Black Box Warnings and the new research on women and HIV, and have an
idea of how to treat the HIV/HCV coinfected patient.
We hope you enjoy this issue of HEPP NEWS. Please provide us with your feedback and com-
ments so that we can continue to provide you with useful information for treating incarcerated
patients with HIV and/or HCV.
Sincerely yours,
David P. Paar
Letter from the Editor
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4were also an independent risk factor for dis-
ease progression. Patients with CD4+ T cell
counts < 200 cells/mm3 were at significantly
greater risk of disease progression than
patients with higher CD4+ T cell counts,
even if antiretroviral therapy was started.
These data again suggest that starting ther-
apy sooner rather than later may be benefi-
cial regardless of the CD4+ T cell count.14
Adverse Effect
Accumulation
Part of the dampening of enthusiasm for
early treatment at the 9th CROI is due to
accumulation of data on adverse events
associated with HAART. The list of adverse
events associated with HAART now
includes: lactic acidosis/ hepatic steatosis,
HAART-associated hepatotoxicity, fat mald-
istribution or lipodystrophy, hyperlipidemia,
osteopenia, skin rash, and new additions to
the HHS guidelines: hyperglycemia,
osteonecrosis, and osteoporosis. And, as
shown in the HIV 101, the list of serious side
effects (issued as "black box" warnings by
the FDA) is growing, with the recent addition
of NNRTI-associated hepatitis (nevirapine)
and NRTI-associated lactic acidosis in asso-
ciation with Guillain-Barré- like neurotoxicity
following severe lactic acidosis (as reported
at the 9th CROI). Skin rash has now become
a class-related adverse event (associated
with NNRTIs).
Emerging Resistance
Reports at the 9th CROI also raised concern
about the impact of drug resistance on future
HAART therapy. This concern is reflected in
the new emphasis in the HHS guidelines on
genotyping at initiation of HAART for individ-
uals in whom acute HIV infection is diag-
nosed. For example, Bennett and col-
leagues studied 923 recently diagnosed
people in 10 US cities (1998-2000) and
noted that resistance to 1 or more antiretro-
viral from any class increased from 3.8% to
9.0% during the study period.15 Grant and
colleagues evaluated viral genotypes in 225
recently infected individuals in San
Francisco, California and found that resis-
tance to any class of drug increased from
16.7% to 27.6% between July 1996 and
2001.16 In contrast, investigators in Sydney,
Australia, failed to observe such an
increase.17 The new HHS guidelines reflect
concerns about the impact of drug resis-
tance on response to initiation of treatment:
"Transmission of drug-resistant strains of
HIV has been documented, and may be
associated with a suboptimal virologic
response to initial antiretroviral therapy. If
the decision is made to initiate therapy in a
individual with acute HIV infection, optimiza-
tion of the initial antiretroviral regimen
through the use of resistance testing is a
reasonable, albeit untested, strategy.
Because of its more rapid turnaround time,
the use of a genotypic assay may be pre-
ferred in this setting." 6
Interrupted therapy and
Immunity
As is well known, in the course of chronic
infection, HIV specific T cells are extremely
activated and active, located in proximity to
dendritic cells (DCs) that not only present
HIV specific epitopes (which activate them)
but also have live virions on their surface.
Therefore the DCs simultaneously activate
and infect CD4+ T helper cells - which then,
in turn, become the target of HIV-specific
CD8+ cytotoxic T cells (CTL). This leads to
the preferential depletion of CD4+ T cells
specific for HIV, as has been described by a
number of expert HIV immunologists includ-
ing B. Autran and Bruce Walker. The
process is termed "depletion of HIV-specific
T helper cells" and is a critical issue at the
heart of controversies related to initiation of
HAART, STI, and therapeutic vaccination.
What happens to the HIV specific CD4+ T
cells? After interruption of HAART (as with
STI), Autran, speaking in the plenary ses-
sion, saw increases in HIV specific CD4+ T
cells that were associated with the rebound
in viremia. The CD4+ T cells rebounded
even before the virus was detectable, and,
alarmingly, usually disappear before the
treatment was re-introduced. She postulated
that these HIV-specific CD4+ T cells are
immediately eliminated (either by HIV-spe-
cific CD8+ T cells or by the direct destruction
of the cell due to viral replication). Thus,
Autran says that STI may actually be prob-
lematic - because as each wave of CD4+ T
cells is re-introduced, they are wiped out by
the HIV-specific CD8+ T cells. This observa-
tion has major implications for patients who
undergo periods of "Unstructured Treatment
Interruption" such as those individuals who
cycle through correctional facilities.
Furthermore, given this information, STI is
bound to fail. 
A related report at the 9th CROI demon-
strated the co-evolution of antibody respons-
es and viral escape, in waves, during infec-
tion. Using a novel HIV entry assay,
Richman and colleagues evaluated the co-
evolution of HIV envelope and neutralizing
antibody from plasma following primary HIV-
1 infection. Most patients (12/14) rapidly
generated strong neutralizing antibody
responses to autologous virus. However,
each sequentially replicating generation of
viruses consistently and rapidly escaped the
concurrent neutralizing antibody response
by developing mutations in the RNA
sequences that code for the neutralizing epi-
topes. The rate of viral neutralization escape
was remarkable and indicated that neutraliz-
ing antibody can exert a previously unappre-
ciated level of selective pressure on viral
evolution. These data have important impli-
cations for natural history and vaccine devel-
opment.18
Stopping Therapy
In a report from CROI that was very relevant
to HIV care in corrections, the EUROSIDA
group evaluated the impact of stopping anti-
retroviral therapy.  They evaluated the clini-
cal outcome of 565 patients in the EUROSI-
DA study who interrupted HAART on their
own. Of the 565, 49% have restarted thera-
py, and 290 developed a new AIDS Related
Event (ARE) or died. Twenty-eight of these
events occurred after being off therapy for at
least 3 months (28/140 person-years = 0.20
per person-year). The relative hazard of a
new ARE or death associated with having
been off therapy for at least 3 months was
2.4 (95% CI 1.6-3.6; p=0.0001) after adjust-
ment for the latest CD4+T cell count and
viral load. These data indicate that risk of
AIDS and death increases more than two
fold upon therapy interruption or stopping.
The absolute risk remains closely linked to
the latest CD4+T cell count and was highest
among patients with a latest CD4+T cell
count below 200/mm3.19
Detecting HIV
Perhaps the most important role that correc-
tions plays in the global AIDS crisis is the
role of testing and educating HIV-infected
in ividuals. At the 9th CROI, Fleming and
colleagues from the Centers for Disease
Control and Prevention (CDC) reported on
the continued spread of HIV in the United
States. They estimated that in 2000,
etween 850,000 and 900,000 people in the
United States were living with HIV infection,
and 40,800 people acquired infection. A
substantial number of people with HIV infec-
tion (between 180,000 and 280,000) are
u aware of this fact, further increasing the
risk for transmission.20
Perhaps more importantly, it is still clear that
many HIV-infected subjects do not know
their status. The goal of the CDC's Project
SAFE (Serostatus Approach to Fighting the
Epidemic) is to bring people into care and
counseling earlier.21 Unfortunately, it now
appears that treatment of HIV-infected indi-
viduals is to be delayed until they achieve
lower CD4+ T cell counts, leading to the
inevitable question from the patient: Why get
tested?   Clearly, because there are so many
individuals who are unaware of their infec-
tion, it is important to continue to test indi-
viduals for HIV. This is particularly true in
corrections, a setting with which many peo-
ple at high risk for HIV infection come into
contact.  While the patient may not see the
benefit of getting tested for HIV, the correc-
tional health care provider must continue to
encourage testing of individuals at risk for
infection. Returning to the image of the
Titanic proposed by Bill Gates, reports pre-
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5sented at the 9th CROI leave us lost at sea, surrounded by dangers
that are half-perceived. The best advice for correctional health care
providers may be to stay tuned in for more changes in course as our
understanding of HIV continues to evolve.
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Correctional Physicians Dilemma: 
Which to Treat First in the Co-infected (HIV/HCV) Patient?
w HIV is advanced
w HCV is stable
w EtOH/drug use still an issue      
(must be totally controlled first)
w Controlling HIV may lower 
HCV  VL and improve 
immune response to HCV
w Early HIV infection, treatment 
not needed yet
w HCV more advanced
w Increased liver damage on 
biopsy
w HCV infection complicating 
HIV treatment
References: Bonacini, M. AIDS Reader.  2002;12(1):19-26./ AIDS Clinical Care. 2002 May; 14 (5):39-43./ HEPP News, April 2002.
Prioritize HIV treatment if . . . Prioritize HCV treatment if . . . 
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Spotlight: An Update on HIV Care for Women
The topic of HIV management in women received hardly any atten-
tion at the 9th CROI, despite recent findings on the gender differ-
ences in CD4+ T cell counts and viral loads at the time of AIDS
diagnosis (Table 1). The significance of these differences remains
to be determined. Overall, the women appear to progress to AIDS
at the same rate as men, given equivalent access to care1, and the
CD4 T cell counts are more similar than they are different2.  Until
large cohort comparisons are performed, it is not clear whether we
should be starting women on treatment using different viral load
thresholds or T cell measurements than are used for men. 
Despite the relative lack of focus on women's issues, a few impor-
tant insights on the management of HIV+ women emerged.  As
presented in one late breaker session that has relevance to the
management of HIV infection in incarcerated women3, HIV
seropositive and HIV seronegative women with biopsy-proven
Squamous Intraepithelial Lesions (SIL) of the cervix were random-
ized to two distinct interventions, based on whether they had low
(LGSIL) or high (HGSIL) grade cervical lesions.  Women with
LGSIL were randomized into observation or cryotherapy; those
with HGSIL received either cryotherapy, LEEP or surgical cone
therapy.  At one year, HIV seropositives with LGSIL were less like-
ly to have a normal pap smear than HIV seronegatives (24% vs.
61% for those being observed without intervention and 56% vs.
95% among those having received cryotherapy).  Only 4% of HIV
seropositive women with LGSIL who were either observed or who
received cryotherapy developed HGSIL at one year. Among HIV
seropositives with severe cervical disease (HGSIL), all treatment
modalities resulted in a much poorer response rate than for HIV
seronegatives. The proportion with a normal pap smear was 29%,
42% and 45% for those receiving cryotherapy, LEEP or cone treat-
ment, respectively (these differences were not statistically signifi-
cant). Thus, no single treatment modality was preferred.  
The take home message for correctional providers is that HIV
seropositive women with SIL do not respond to standard cervical
therapies as well as HIV seronegatives. However, those HIV
seropositive women with LGSIL may not need immediate inter-
ventions as was once thought because the rate of progression is
not fast. Among HIV seropositive women with HGSIL, therapy is
indicated; however there does not appear to be any preferred
treatment modality.  Correctional providers should also recognize
that if treatment is delayed and the patient leaves the correctional
facility, the careful follow-up available in the correctional system
may be lost and the disease may progress without further care,
resulting in increased morbidity and mortality in the community.
Until data points to the contrary, Pap smear abnormalities should
continue to be followed up and treated in a timely fashion.
Mother-to-child transmission (MTCT) of HIV was another topic per-
tinent to both women and children that was reviewed at the 9th
CROI. Judith Currier4 summarized recent findings from PACTG
(Pediatric AIDS Clinical Trials Group) 316 (use of single-dose nevi-
rapine to mother and infant in addition to other maternal antiretro-
virals during pregnancy)5 which demonstrated that it is possible to
reduce MTCT rates from the 8% observed in the famous 076 study
(AZT monotherapy) to 1.6% with the use of potent combination
antiretroviral therapy. Lower viral loads had a dramatic effect on
the transmission of HIV: among women with HIV-1 RNA <1000
copies/mL throughout pregnancy, transmission rates were 1.8%
with a single antiretroviral agent and 0.8% when multiple agents
were used. In addition, for women whose last measure of virus
load during pregnancy was <1000 copies/mL, transmission rates
were <1%.6
Data were presented from 2,087 pregnancies of HIV-infected
women since January 1998 in a review of PACTG 367. Given
excellent care (97% received prenatal care, and 60% were on pro-
tease inhibitors) there were no significant differences between
vaginal delivery and elective C-section delivery; however, when
only intrapartum transmissions were considered, the transmission
rates during vaginal deliveries and elective C-sections were 3.4%
and 1.7%, respectively, a difference that approached statistical sig-
nificance. 
Due to concern about serious adverse events related to lactic aci-
dosis, warnings on the use of d4T and ddI during pregnancy have
been issued (FDA, package inserts). According to one report
(AERS), 8 pregnant women developed pancreatitis and/or lactic
acidosis at 32 weeks gestation. In 7/8 (88%) cases, the patient was
taking the combination of ddI and d4T. The eighth patient was tak-
ing d4T and 3TC. Among the 7 women taking ddI and d4T, 3 died.
Fetal death was documented in 3 of these cases, including the
woman taking d4T and 3TC. These resesarchers found that the
combination use of d4T and ddI during pregnancy increased the
risk of development of lactic acidosis and/or pancreatitis, that the
risk appears to be greatest in the third trimester and with longer
duration of ddI/d4T therapy. Based on these findings, ddI/d4T ther-
apy should be given only to those pregnant women in whom the
potential benefits clearly outweigh the risks.7
DISCLOSURES:
*Consultant and Speaker's Bureau: Abbott Laboratories, Boehringer
Ingelheim, Roche, Agouron, Bristol Myers Squibb, GlaxoSmithKline,
Gilead Sciences, Ortho Biotech and Merck Pharmaceuticals.
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Table 1: Differences Between Men and Women in 
HIV Disease
CD4 Count
at AIDS
146
49
CD4 Count
at Death
44
22
Baseline
RNA 
(b-DNA)
3365
8907
Follow-Up
RNA 
(RT-PCR)
45,416
93,130
Women
Men
by Rick Altice, M.D.*, Yale HIV in Prisons Program
Correction: In the April 2002 issue of HEPP News, in the section titled "HIV/HCV Response to Therapy," there are references to studies
demonstrating the efficacy of pegylated interferon/ribavirin combination therapy in coinfected patients. The pegylated interferon used in
these studies was pegylated interferon alfa 2a (Pegasys, Roche), NOT the pegylated interferon alfa 2b (PEG-Intron, Schering) that had
been discussed earlier in the article. Furthermore, in the HIV101, it was not made clear that dosing ribavirin by weight, used with stan-
dard interferons, has not been FDA approved for use with pegylated interferon alfa 2b (PEG-Intron), although some experts believe that
the data can be extrapolated. This is based on a retrospective analysis of a study in which some lighter weight patients received only
800 mg ribavirin. PEG-intron is currently only FDA approved for use with 800 mg daily ribavirin.
7"Black Box Warnings" For Antiretroviral Medications
Antiretroviral Drug 
Generic Name (Abbr., Brand name, Mfr.)
Black Box Warnings
NRTIs (Nucleoside Reverse Transcriptase Inhibitors)
Abacavir (ABC, Ziagen,
GlaxoSmithKline [GSK]) or as Trizivir** 
See HEPP News January 2002,
HEPPigram, p. 5
Didanosine (ddI, Videx, Videx-EC,
Bristol Myers-Squibb [BMS])
Lamivudine (3TC, Epivir, GSK) or as
Combivir* or Trizivir**
Stavudine (d4T, Zerit, BMS)
Zidovudine (AZT, Retrovir, GSK) or as
Combivir* or Trizivir**
Tenofovir (TDF, Viread, Gilead)
Nevirapine (NVP, Viramune,
Boehringer-Ingelheim)
Amprenavir Oral Solution (APV,
Agenerase, GSK) 
Ritonavir (RTV, Norvir, Abbott
Laboratories)
Ø Fatal hypersensitivity reactions:
w Signs/Symptoms: fever, skin rash, fatigue, GI and respiratory symptoms
w ABC should be discontinued as soon ashypersensitivity is suspected
w ABC SHOULD NOT be restarted; If restarted, more severe symptoms will recur 
within hours and may include life-threatening hypotension and death
w ABC sensitivity syndrome should be noted on the patient's chart 
Note that Trizivir contains ABC and sensitivity to Trizivir should be noted as well
Ø Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have
been reported with the use of antiretroviral nucleoside analogues alone or in combination
Ø Fatal and nonfatal pancreatitis have occurred with ddI alone or in combination with
other antiretroviral agents
w ddI should be held if pancreatitis is suspected and should be discontinued if 
pancreatitis is confirmed
Ø See fatal lactic acidosis above (in abacavir box)
Ø Fatal lactic acidosis has been reported in pregnant women who received a combina-
tion of ddI and d4T along with other antiretroviral combinations, therefore, ddI and d4T
combination should only be used during pregnancy if the potential benefits clearly out-
weigh the potential risks
Ø See lactic acidosis above (in abacavir box)
Ø See lactic acidosis above (in abacavir box)
Ø See fatal lactic acidosis above (in didanosine box)
Ø Fatal and non-fatal pancreatitis have occurred when d4T was part of a combination
regimen with ddI with or without hydroxyurea
Ø Potentially fatal neuromuscular reaction mimicking Guillain-Barre syndrome has been
reported
Ø AZT may be associated with hematologic toxicities, inluding granulocytopenia and
severe anemia, particularly in advanced HIV patients
Ø Prolonged AZT use has been associated with symptomatic myopathy
Ø See lactic acidosis above (in abacavir box)
Ø See lactic acidosis above (in abacavir box)
Ø Severe, life-threatening hepatotoxicity, including fulminant and cholestatic hepatitis,
hepatic necrosis, and hepatic failure. Patients should be advised to seek medical evalua-
tion immediately should signs and symptoms of hepatitis occur.
Ø Severe, life-threatening, and even fatal skin reactions, including Stevens-Johnson syn-
drome, toxic epidermal necrolysis, and hypersensitivity reactions characterized by rash,
constitutional findings, and organ dysfunction have occurred with NVP treatment
Ø Patients should be monitored intensively during the first 12 weeks of NVP therapy to
detect potentially life-threatening hepatotoxicity or skin reactions.
Ø A 14-day lead-in period with NVP 200mg daily must be strictly followed.
Ø NVP should not be restarted after severe hepatic, skin, or hypersensitivity reactions
Ø Because of potential risk of toxicity from large amounts of the excipient propylene gly-
col in APV Oral Solution, it is contraindicated in: children < 4 years old; pregnant women;
patients with renal or hepatic failure; patients treated with disulfiram or metronidazole
Ø Oral solution should be used only when APV capsules or other PIs cannot be used
Ø Co-administration of RTV with certain medications may result in potentially serious
and/or life-threatening adverse events due to effects of RTV on hepatic metabolism of
certain drugs
Special note: Providers need to note the following combination therapies as dangerous reactions that apply to any of the drugs in the combination form
apply to the combination therapy as well:* Combivir, GSK = Lamivudine + Zidovudine; ** Trizivir, GSK = Lamivudine + Zidovudine + Abacavir
The following antiretrovirals have no "black box warnings" (see guidelines for full information on other toxicities): Delavirdine (Resciptor, Pharmacia &
Upjohn); Efavirenz (Sustiva, BMS); Indinavir (Crixivan, Merck & Co.); Lopinavir/Ritonavir (Kaletra, Abbott Labs); Nelfinavor (Viracept, Agouron);
Saquinavir (Invirase, Fortovase, Hoffman-LaRoche).
Adapted from: HHS Adult and Adolescent Guidelines, Table 16 (p.49-50).
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Certain medications are associated with adverse events. Those adverse events that may lead to death or serious injury are often
required (by the FDA) to be placed in a prominent box, known as the "black box" on the product insert. Presented here are anti-
retroviral medications along with their "black box warnings". Note that there may be other toxicities associated with these medica-
tions that are listed in the current HHS guidelines, available at http://www.hivatis.org/guidelines/adult/Feb04_02/AdultGdl.pdf.
NNRTIs (Non-Nucleoside Reverse Transcriptase Inhibitors)
Nucleotide Reverse Transcriptase Inhibitor
PIs (Protease Inhibitors)
Sixth Annual HIV Update:
Contemporary Issues in
Management
June 6-8, 2002
Boston, Massachusetts
Fee: After April 26: $595, $375
Residents and Fellows
Call: 617.384.8600
Fax: 617.284.8686
Email: hms-
cme@hms.harvard.edu
Continuing ed. credit available
Management of Hepatitis C:
2002
June 10-12, 2002
Bethesda, Maryland
Sponsored by the National
Institutes of Health (NIH)
Fee: None
Visit: http://consensus.nih.gov
Conference can be viewed via the
Internet at http://videocast.nih.gov
Call: 301.592.3320 
Fax: 301.593.9433
Email: hepc@prospectassoc.com
10th National Roundtable for
Women in Prison
June 20-23, 2002
New York, New York
Fee: After May 15: $175
Visit: www.wpaonline.org
Email: rnelson@wpaonline.org or
tkingsley@wpaonline.org
XIV International AIDS
Conference
July 7-12, 2002
Barcelona, Spain
Fee: After May 1: $1050 (special
rates and scholarships available)
Visit: www.aids2002.com
Email: aids2002.registration@
congrex.se
6th Annual United States
Conference on AIDS (USCA)
September 19-22, 2002
Anaheim, California
Fee: Before June 14th - 
$330 members/
$400 non-members; 
before August 23- $375/$450
Visit: www.nmac.org/usca2002/
Call: Paul Woods, 
202.483.6622 ext. 343
Email: pwoods@nmac.org
Save the 
Dates
8
HCV
New Data Shows High SVR For Genotype 1
Patients on Pegylated Interferon (Pegasys)
hivandhepatitis.com, 4/18/02, www.easl.ch
At the European Association for the Study of the
Liver (EASL) meeting in April, Roche presented
data from prospective trials with its new pegylat-
ed interferon, Pegasys. Overall (including results
from all HCV genotypes), the data showed a
sustained virologic response (SVR; see HEPP
News, April 2002) rate of 61%; for patients with
genotype 1 HCV, (the most common and the
hardest to treat) the SVR rate was 51%, the
highest SVR for genotype 1 patients seen thus
far. These patients received 180 micrograms of
Pegasys once per week along with 1000mg (if
<75kg) or 1200mg (if >75 kg) of ribavirin per day
for 48 weeks.  Patients with genotype 2 or 3 who
received 180mg of Pegasys once per week
along with the lower 800 mg of ribavirin for 24
weeks achieved an SVR of 78%. Roche expects
FDA approval of Pegasys later this year. 
HIV
Tenofovir Increases DDI Levels in Blood
Bristol-Meyers Squibb Letter to Health Care
Professionals, 5/02
A new study on the pharmacokinetics of ddI
(Videx, BMS) and tenofovir (Viread, Gilead) has
shown that administration of ddI, in the extended
formulation or in the capsular form, one hour
before tenofovir DF 300 mg QD (both in the fast-
ing state) results in roughly a 40% increase in
didanosine exposure relative to the administra-
tion of ddI (EC or tablets) 400 mg alone in the
fasted state. Furthermore, if the two drugs are
co-administered with a light meal, there is an
even greater (50 to 60% increase in ddI expo-
sure, tablet and EC, respectively) relative to ddI
given alone in the fasting state. The impact of
this increase is not clear, but ddI side effects may
become more pronounced when ddI is used with
tenofovir. Providers are encouraged to monitor
patients taking standard doses of ddI and teno-
fovir for adverse events related to these drugs
(see HIV101 for Black Box Warnings). 
Mandatory Testing Before Release?
Miami Herald, 4/23/02
A bill passed by the Florida State legislature and
senate would make HIV testing mandatory for all
inmates 60 days prior to release. According to
the legislation, inmates who test positive for HIV
will be provided with a 30-day supply of medica-
tions upon release. Some corrections experts
believe the legislature has not truly comprehend-
ed the price tag for this proposed legislation, as
the legislature appropriated slightly more than
half of the funds the Department of Corrections
requested to cover the cost of the program.
HIV Seroprevalence of New York State DOC
Inmates Drops Over the Past 12 Years
Abstract 767-W, 9th CROI
A study examining HIV infection in New York
State correctional facilities found that the sero-
prevalence among female inmates dropped from
18.8% in 1988 to 13.9% in 2000.  Among male
inmates, the HIV seroprevalence dropped from
17.6% to 4.7% in the same time period.  Injection
drug use also decreased from 1988 to 2000,
dropping from about 28% for both male and
female inmates to 5.8% for male inmates and
14.5% for female inmates.  Experts recommend
that more prevention services be offered to
parolees and jail inmates.
Valganciclovir Effective as Induction Therapy
for CMV
NEJM 2002; 346 (15): 1119-1126.
A new study has shown that oral valganciclovir
(Valcyte, Roche) is as effective in induction ther-
apy for cytomegalovirus (CMV) as the intra-
venous ganciclovir traditionally used.
Valganciclovir, in its oral form, is more conve-
nient for most patients than an intravenous drug.
TB
HEPP TB Article: CDC Communication
According to the CDC, total numbers of TB
cases in the United States have declined 39%
since 1992. The decline of TB in corrections has
been even greater: there were 588 cases of TB
in corrections in 2000, compared with 1065
cases in 1994, a decline of 45%.  Furthermore,
the case rate of TB in corrections stated on p.2
of the March 2002 issue of HEPP may be over-
stated as the "% of Population Incarcerated" in
Table 1 (p.1) did not take into account those per-
sons incarcerated in local and county facilities,
thereby understating the percent of the state
population that is incarcerated. 
Inside News
Resources & Websites
9th Annual Conferences on Retroviruses and
Opportunistic Infections
http://www.retroconference.org/2002/
New Bureau of Justice Statistics Report: Prison
and Jail Inmates at Midyear 2001
http://www.ojp.usdoj.gov/bjs/pub/pdf/pjim01.pdf
Correctional Health Care: Guidelines for the
Management of an Adequate Delivery System,
2001 Update
http://www.nicic.org/pubs/2001/017521.htm
Three Part Report: "Corrections, Inc."
American Radio Works report explores aspects of
the correctional industry, listen or read at 
http://www.americanradioworks.org/features/
corrections/index.html
amfAR HIV/AIDS Treatment Directory, 
2002 Winter Edition
Free (incl. shipping); Large quantities available 
for clinic settings.
Contact Gretchen.Schmelz@amfar.org or 
call 212.806.1762
Updated HHS Guidelines for the Use of
Antiretrovirals in Pregnant Women
http://www.hivatis.org/guidelines/perinatal/Feb4_02/
Perin.pdf
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Self-Assessment Test for Continuing Medical Education Credit
Brown Medical School designates this educational activity for 1 hour in category 1 credit toward the AMA Physician’s Recognition Award.
To be eligible for CME credit, answer the questions below by circling the letter next to the correct answer to each of the questions. 
A minimum of 70% of the questions must be answered correctly. This activity is eligible for CME credit through December 31, 2002. 
The estimated time for completion of this activity is one hour and there is no fee for participation.
1. For an HIV-positive, asymptomatic patient with a CD4+ T cell
count of 500 cells/mm3 and a viral load of 15,000 copies, what do
the majority of experts say should be done?
a) Treat the patient aggressively and immediately
b) Wait to treat the patient until the CD4+ T cell count falls below 
400 cells/mm3, regardless of viral load
c) Defer therapy and observe the patient 
d) Defer therapy until the patient is symptomatic 
e) None of the above
2. Which of the following adverse events has been associated with
HAART?
a) lactic acidosis/hepatic steatosis
b) osteoporosis
c) skin rash
d) NNRTI-associated hepatitis
e) All of the above
3. The CDC estimates that between 20% and 30% of HIV-positive
people in the United States do not know they are infected.
a) True
b) False
4. "Lactic acidosis and sever hepatomegaly with steatosis, includ-
ing fatal cases, have been reported with the use of antiretroviral
nuceloside analogues alone or in combination." To which class(es)
of antiretroviral drugs does this statement apply?
a) NNRTIs
b) NRTIs
c) PIs
d) NRTIs and Nucleotide Reverse Transcriptase Inhibitors
e) NRTIs, NNRTIs, and PIs
5. New information presented at the 9th CROI discussed which of
the following findings related to SIL?
a) HIV-positive women with LGSIL were less likely to have a 
normal Pap Smear than HIV-negatives at one year of follow-up
b)  HIV seropositives with HGSIL had much poorer responses to 
treatments than HIV seronegatives
c) No single treatment modality (i.e. cryotherapy, LEEP or cone 
treatment) was preferred for HIV-seropositive women with 
HGSIL
d) HIV-positive women do not respond to cervical therapies as 
well as HIV-negative women
e) all of the above
6. A patient is coinfected with both HIV and HCV. A biopsy was
done and showed moderate cirrhosis of the liver. The patient’s
ALTs and LFTs are outside the normal range. The HIV has been
recently diagnosed, and the patient has a CD4+ T cell count of 500
cel s/mL and a viral load of 35,000 copies/mL. Which infection
should the provider consider treating first?
a) HIV
b) HCV
c) treat both infections simultaneously
d) neither
e) begin HIV treatment first; when viral load is undetectable, 
then begin treating the HCV
BROWN MEDICAL SCHOOL •  OFFICE OF CONTINUING MEDICAL EDUCATION •  BOX G-A2  •  PROVIDENCE, RI 02912
The Brown Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME)to provide continuing medical 
education activities for physicians.  
The use of the Brown Medical School name implies review of the educational format and material only.  The opinions, recommendations 
and editorial positions expressed by those whose input is included in this bulletin are their own.  They do not represent or speak for the 
Brown Medical School.
For Continuing Medical Education credit please complete the following and mail or fax to 401.863.2660 or 
register online at www.hivcorrections.org. Be sure to print clearly so that we have the correct information for you.
Name __________________________________________________________________ Degree ____________________
Address ____________________________________________________________________________________________
____________________________________________________________________________________________________
City ____________________________________________________ State ________ Zip ________________________
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HEPP News Evaluation
5 Excellent    4 Very Good    3 Fair    2 Poor    1 Very Poor
1. Please evaluate the following sections with respect to:
educational value clarity
Main Article 5  4  3  2  1   5  4  3  2  1     
HEPPigram 5  4  3  2  1   5  4  3  2  1  
HIV 101 5  4  3  2  1   5  4  3  2  1
Save the
Dates 5  4  3  2  1   5  4  3  2  1
2. Do you feel that HEPP News helps you in your work?
Why or why not?
3. What future topics should HEPP News address?
4. How can HEPPNews be made more useful to you?
5. Do you have specific comments on this issue?
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